Global Placental Stem Cell Therapy Market

Placental Stem Cell Therapy Market Insights

Placental stem cells are cells derived from the placental blood and other body fluids of a new-born baby. Perinatal refers to the period immediately preceding and following birth. Perinatal stem cells can be found in abundance in both placental blood and tissues. The cord blood stem cells and umbilical cord tissues are two other placenta components. Hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) are abundant in these body tissues. Hematopoietic progenitor and hematopoietic stem cells (HSCs) are abundant in the human placenta and cord blood, and they eventually lead to rise in all forms of blood cells, including myeloid (monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes/platelets, and dendritic cells) and lymphoid (T-cells and NK Cells).   

Stem cells are human cells classified into a different variety of cell types, including brain and muscle cells. Stem cells are sometimes used in the development of regenerative therapies. Regenerative medicine represents a category of scientific alternatives to stem cell therapy (such as tissue regeneration). These treatments include the capacity to regenerate human cells, tissues, or organs to return the body to healthy working. Stem cell therapies are used to cure and improve diseases like spinal cord injuries, Parkinson's disease, heart disease, and diabetes.

Stem cell treatment has been credited with bringing in major and innovative advances in cancer control and health care. Cancer and vascular disorders can all be effectively treated with these products. Stem cell therapy has risen as a potential candidate in the area of gene therapy for the repair or reconstruction of weakened tissues in recent times. Furthermore, the industry is becoming more mindful of the medicinal potential of stem cells for disease control. The use of placental stem cells as a treatment for serious COVID-19 is gaining momentum as a feasible choice.

The use of system cell therapy to treat COVID -19 has recently seen growth in the market. The human placenta has positive effects on the immune system, as well as the therapeutic applicability of placental parts including amniotic membranes for wound recovery, burn care, and oral cavity repair, which are helping in growing this market. The growing number of experimental scientific research focusing on using the treatment effectiveness of stem cells for disease treatment, as well as the introduction of stem cell line banking, are helping in the growth of the stem cell therapy industry. The growth of this industry has also been aided by the advancement of induced pluripotent stem cell lines. The advancement of regenerative medicines also is adding fuel to drive the market for stem cells.  

Placental Stem Cell Therapy Market: By Application

Based on the application, the Placental Stem Cell Therapy market can be differentiated as Hematologic Malignancies Disorders, Neurological Disorders, Congenital Immunodeficiency Disorders, and Metabolic Disorders. The congenital Immunodeficiency disorders will be the growing segment during the coming years. The world recently has been hit by Covid-19 and hence people are more focusing on their immune systems to fight against this deadly disease. People also have understood the importance of keeping their immune system fit and healthy as it helps to fight against any disease and if any treatment, which is available to cure diseases or to keep the immune system healthy comes, people will surely go for it and hence this segment will grow in the coming time frame.

Placental Stem Cell Therapy Market: By End-User

Based on end-user, the Placental Stem Cell Therapy market is divided into Hospitals, Research Institutes, Specialty Clinics, Clinical Research Organizations, and research Academies among others. The hospitals and clinics segment is likely to hold the major chunk of market share in the global market. The cell therapies project to treat various diseases like cancer and others & have rapidly grown during the years. The therapy is also used to cure severe covid-19 cases and hence the hospital segment is likely to grow.

Placental Stem Cell Therapy Market: By Region

Based on the research, the North American region will be a dominating segment in the regional analysis. The growing technological advancements in the field of healthcare and increasing research activities in the stem cell department are boosting the market growth. The growing usage and focus on regenerative medicines in the U.S. are also boosting regional growth. The improving personalized cellular therapies are driving the market growth. The Asia Pacific region will hold the second position in the global market. The growing government funding in the healthcare sector and the presence of a huge base of biotech companies are supporting regional growth.

Stem cell treatments are used for treating a variety of illnesses and accidents. The Asia pacific stem cell therapy industry is assumed to expand at a significant pace throughout the next decade, with many public and private foundations actively financing and supporting stem cell-based research initiatives. The stem cell therapy industry includes a variety of stem cell-based drugs that are used to treat a variety of diseases, including cancer, tissue regeneration, injuries, and accidents.

Placental Stem Cell Therapy Market Share and Competitor Analysis

Lifebank Stem Cell Banking, Cynata, Celularity, Inc., Athersys, Inc, Americord Registry, ReNeuron Group plc, ReeLabs Pvt. Ltd., Mesoblast Limited, Pluristem Therapeutics, Inc., and Mesoblast Limited, are the key companies involved in developing placental stem cell therapies.

Please note: This is not an exhaustive list of companies profiled in the report.